AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15249525 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt access to physiotherapy (physiotherapist clinics established in primary care)
Number of subjects: 614
Study 15249525 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt access to physiotherapy
Number of subjects: 614
Study 11359031 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally obese subjects (WHR >=0.81 for women and >=0.92 for men)
Number of subjects: 77
Study 11359031 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripherally obese subjects (WHR <0.81 for women and <0.92 for men)
Number of subjects: 77
Study 11359031 — intervention group
Group type: COMPARATOR
Intervention: Controls (BMI <27.8 for men and <27.3 for women)
Number of subjects: 77
Study 9286741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg/day for 8 days)
Number of subjects: 12
Study 9286741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8356859 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 20 ml of 0.125% bupivacaine and 2 mg of morphine administered epidurally about 30 min before the end of the operation
Number of subjects: 14
Study 8356859 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone with nitrous oxide, oxygen and enflurane (control group)
Number of subjects: 14
Study 2887190 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50-100 mg day-1
Number of subjects: 40
Study 2887190 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200-800 mg day-1
Number of subjects: 40
Study 2887190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10-30 mg day-1
Number of subjects: 40
Study 2887190 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25-100 mg day-1
Number of subjects: 40
Study 2887190 — intervention group
Group type: EXPERIMENTAL
Intervention: All four drugs
Number of subjects: 40
Study 30382819 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung approach (OLA) with PEEP titration, external PEEP selected was 6 ± 0.8 cmH2O.
Number of subjects: 13
Study 30382819 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung approach (OLA) with PEEP titration.
Number of subjects: 13
Study 27965838 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate tumor resection after stopping chemotherapy
Number of subjects: 84
Study 27965838 — intervention group
Group type: COMPARATOR
Intervention: Completion of chemotherapy before surgery
Number of subjects: 84
Study 24610807 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-CRT
Number of subjects: 682
Study 23012311 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback letter intervention sent to 72 alcohol outlets
Number of subjects: 146
Study 23012311 — intervention group
Group type: COMPARATOR
Intervention: Control group (74 outlets)
Number of subjects: 146
Study 23012311 — intervention group
Group type: COMPARATOR
Intervention: Interviews with outlets regarding handling of the intervention
Number of subjects: 146
Study 20806998 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 55
Study 20806998 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture (SEA)
Number of subjects: 55
Study 18975535 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ketamine (300-400 microg x kg(‐1) x hr(‐))
Number of subjects: 40
Study 18975535 — intervention group
Group type: COMPARATOR
Intervention: Saline (control) group
Number of subjects: 40
Study 16875724 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Prescription Model (EPM) - 30-minute continuous activity, 3-4 days per week
Number of subjects: 50
Study 16875724 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle group (LIFE) - 6-minute activity, 5 times per day, 4-5 days per week
Number of subjects: 50
Study 12954465 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Geriatric Assessment Team (MGAT)
Number of subjects: 265
Study 12954465 — intervention group
Group type: COMPARATOR
Intervention: Barthel Index
Number of subjects: 265
Study 12954465 — intervention group
Group type: COMPARATOR
Intervention: Physical Self‐Maintenance Scale
Number of subjects: 265
Study 12954465 — intervention group
Group type: COMPARATOR
Intervention: Instrumental Activities of Daily Living
Number of subjects: 265
Study 12954465 — intervention group
Group type: COMPARATOR
Intervention: modified Spitzer Quality of Life Index
Number of subjects: 265
Study 10812039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mol/L sodium lactate infused over 20 min
Number of subjects: 0
Study 10812039 — intervention group
Group type: COMPARATOR
Intervention: Placebo infused over 20 min
Number of subjects: 0
Study 9017056 — intervention group
Group type: EXPERIMENTAL
Intervention: Amvisc with aspiration and topical timolol
Number of subjects: 0
Study 9017056 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (Blocadren)
Number of subjects: 0
Study 9017056 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 0
Study 9017056 — intervention group
Group type: COMPARATOR
Intervention: Amvisc without aspiration
Number of subjects: 0
Study 9017056 — intervention group
Group type: COMPARATOR
Intervention: Healon with aspiration
Number of subjects: 0
Study 9017056 — intervention group
Group type: COMPARATOR
Intervention: Amvisc without timolol
Number of subjects: 0
Study 9017056 — intervention group
Group type: COMPARATOR
Intervention: Healon without timolol
Number of subjects: 0
Study 1517815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatin (CDDP)
Number of subjects: 79
Study 1517815 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin (CDDP)
Number of subjects: 79
Study 1517815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IA CDDP and IV CDDP)
Number of subjects: 79
Study 6576623 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized breakfast stimulation
Number of subjects: 49
Study 6576623 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. glucose + i.v. arginine stimulation
Number of subjects: 49
Study 6576623 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour profile of serum C-peptide
Number of subjects: 49
Study 6576623 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary C-peptide
Number of subjects: 49
Study 28714759 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping group (KTG)
Number of subjects: 86
Study 28714759 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid taping group (RTG)
Number of subjects: 86
Study 28714759 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo kinesio taping)
Number of subjects: 86
Study 28714759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no taping)
Number of subjects: 86
Study 30323559 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 942
Study 27091603 — intervention group
Group type: EXPERIMENTAL
Intervention: CHILE intervention
Number of subjects: 655
Study 27091603 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 655
Study 24531687 — intervention group
Group type: EXPERIMENTAL
Intervention: PG201 600 mg
Number of subjects: 309
Study 24531687 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 309
Study 22259009 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson 0.4 mg intravenous injection
Number of subjects: 432
Study 22259009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 19473285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg taken once daily
Number of subjects: 342
Study 19473285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 17891597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 20 microg plus levonorgestrel 100 microg (EE20/LNG100)
Number of subjects: 78
Study 17891597 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 78
Study 15365570 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan monotherapy (350 mg m(‐2) once every 3 weeks)
Number of subjects: 339
Study 11239541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg; n = 50)
Number of subjects: 100
Study 11239541 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined 17-beta-estradiol (2 mg) and norethindrone acetate (1 mg; n = 50)
Number of subjects: 100
Study 9737353 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone, 10 mg twice daily
Number of subjects: 48
Study 7508194 — intervention group
Group type: EXPERIMENTAL
Intervention: Human galanin (500 micrograms) in saline (100 ml)
Number of subjects: 6
Study 7508194 — intervention group
Group type: COMPARATOR
Intervention: Saline (100 ml)
Number of subjects: 6
Study 2727326 — intervention group
Group type: EXPERIMENTAL
Intervention: Open mouth breathing
Number of subjects: 78
Study 2727326 — intervention group
Group type: COMPARATOR
Intervention: Tachypnea
Number of subjects: 78
Study 2727326 — intervention group
Group type: COMPARATOR
Intervention: Hyperpnea
Number of subjects: 78
Study 2727326 — intervention group
Group type: COMPARATOR
Intervention: Combination of breathing patterns
Number of subjects: 78
Study 30099398 — intervention group
Group type: EXPERIMENTAL
Intervention: Case method learning (CM)
Number of subjects: 255
Study 30099398 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lectures (TL)
Number of subjects: 255
Study 30099398 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no CME)
Number of subjects: 255
Study 26220762 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone
Number of subjects: 14
Study 26220762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone-dexmedetomidine (0.3 mg 100 mL(‐1))
Number of subjects: 14
Study 25660434 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/d
Number of subjects: 30
Study 25660434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23982301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 73
Study 23982301 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active placebo)
Number of subjects: 73
Study 19854114 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI)
Number of subjects: 204
Study 19854114 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of positive axillary node(s)
Number of subjects: 204
Study 19854114 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of estrogen receptor (ER) negative tumor
Number of subjects: 204
Study 18435852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone added to metformin
Number of subjects: 759
Study 18435852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone added to sulfonylureas
Number of subjects: 759
Study 17158431 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 26
Study 17158431 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 26
Study 14722364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 451
Study 14722364 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg elemental iron)
Number of subjects: 451
Study 14722364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education with supplementation (20 mg elemental iron)
Number of subjects: 451
Study 14722364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 451
Study 10745678 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mL black currant/apple juice (1:1)
Number of subjects: 5
Study 10745678 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mL black currant/apple juice (1:1)
Number of subjects: 5
Study 10745678 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mL black currant/apple juice (1:1)
Number of subjects: 5
Study 10745678 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice intervention (all doses)
Number of subjects: 5
Study 8792117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 86
Study 8792117 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 86
Study 1291401 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 2
Study 1291401 — intervention group
Group type: EXPERIMENTAL
Intervention: clioquinol
Number of subjects: 2
Study 1291401 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study 1291401 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxacin
Number of subjects: 2
Study 1291401 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP/SMX
Number of subjects: 2
Study 3881960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen-androgen drug
Number of subjects: 0
Study 3881960 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen alone
Number of subjects: 0
Study 3881960 — intervention group
Group type: COMPARATOR
Intervention: Estrogen alone
Number of subjects: 0
Study 3881960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31036708 — intervention group
Group type: COMPARATOR
Intervention: Hip prosthesis constructs (various brands)
Number of subjects: 4442
Study 29790266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clindamycin 300 mg twice daily for 5 days
Number of subjects: 1727
Study 29790266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1727
Study 26600073 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven days a week individual therapy
Number of subjects: 10
Study 26600073 — intervention group
Group type: COMPARATOR
Intervention: Five days a week circuit class therapy
Number of subjects: 10
Study 24887381 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplo‐HSCT
Number of subjects: 410
Study 24887381 — intervention group
Group type: COMPARATOR
Intervention: UCBT
Number of subjects: 410
Study 22305998 — intervention group
Group type: EXPERIMENTAL
Intervention: aliskiren/amlodipine/HCTZ 300/10/25 mg
Number of subjects: 412
Study 22305998 — intervention group
Group type: COMPARATOR
Intervention: aliskiren/amlodipine 300/10 mg
Number of subjects: 412
Study 19806530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (AI) for the prevention of MAS
Number of subjects: 0
Study 18363895 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg clevudine once daily for 12 weeks
Number of subjects: 31
Study 18363895 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg clevudine once daily for 12 weeks
Number of subjects: 31
Study 18363895 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg clevudine once daily for 12 weeks
Number of subjects: 31
Study 18363895 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine overall
Number of subjects: 31
Study 16240065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation using an oral sodium phosphate solution and rectal enema on the morning of the procedure.
Number of subjects: 101
Study 16240065 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation (control group).
Number of subjects: 101
Study 16240065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation group.
Number of subjects: 101
Study 11884902 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive intervention
Number of subjects: 6176
Study 11884902 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intervention
Number of subjects: 6176
Study 11884902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6176
Study 9505096 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention (HIV risk reduction education, HIV testing with pretest and posttest counseling, training in condom use and needle cleaning)
Number of subjects: 684
Study 9505096 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (additional information on STD risk reduction)
Number of subjects: 684
Study 9505096 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 684
Study 9505096 — intervention group
Group type: COMPARATOR
Intervention: Enhanced intervention
Number of subjects: 684
Study 7796353 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporotic subjects
Number of subjects: 0
Study 7796353 — intervention group
Group type: COMPARATOR
Intervention: Nonosteoporotic subjects
Number of subjects: 0
Study 2195013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 2195013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 40 mg
Number of subjects: 9
Study 522637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29185780 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron capsules (15 mg/twice daily)
Number of subjects: 100
Study 29185780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28864400 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 22
Study 28864400 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 22
Study 26445158 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed exercise intensity at 40% of one-repetition maximum (1RM)
Number of subjects: 16
Study 26445158 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed exercise intensity at 60% of one-repetition maximum (1RM)
Number of subjects: 16
Study 26445158 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed exercise intensity at 80% of one-repetition maximum (1RM)
Number of subjects: 16
Study 26445158 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity
Number of subjects: 16
Study 26445158 — intervention group
Group type: COMPARATOR
Intervention: Control condition without exercise
Number of subjects: 16
Study 23926422 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (25-100 mg/day, mean 67.6 mg/day)
Number of subjects: 52
Study 23926422 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (0.5-2.0 mg/day, mean 0.8 mg/day)
Number of subjects: 52
Study 23926422 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 52
Study 23926422 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 52
Study 21425514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 100
Study 21425514 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation guidance
Number of subjects: 100
Study 18475003 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P Level 4 interventions
Number of subjects: 0
Study 17198445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse intravenous methylprednisolone (1000 mg for 4 days) plus cyclophosphamide (500 mg for 1 day)
Number of subjects: 123
Study 17198445 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (1-2 mg/kg/day for 28 days) plus azathioprine (1.5 mg/kg/day)
Number of subjects: 123
Study 12749513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg QD for 5 days
Number of subjects: 86
Study 12749513 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2 to 5
Number of subjects: 86
Study 11136302 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist cuff during venous occlusion
Number of subjects: 8
Study 11136302 — intervention group
Group type: COMPARATOR
Intervention: No wrist cuff during venous occlusion
Number of subjects: 8
Study 9554155 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot method using 8 kDa antigenic fraction
Number of subjects: 47
Study 9554155 — intervention group
Group type: COMPARATOR
Intervention: Indirect haemagglutination, immunoelectrophoresis, and ELISA
Number of subjects: 47
Study 1316079 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily 400 mg lomefloxacin
Number of subjects: 100
Study 1316079 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily 400 mg lomefloxacin
Number of subjects: 100
Study 2931232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once a day)
Number of subjects: 20
Study 2931232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet once a day)
Number of subjects: 20
Study 29889058 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ training program for 12 weeks (five times per week)
Number of subjects: 57
Study 29889058 — intervention group
Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 57
Study 27598763 — intervention group
Group type: EXPERIMENTAL
Intervention: Celebrity images
Number of subjects: 138
Study 27598763 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer images
Number of subjects: 138
Study 27598763 — intervention group
Group type: COMPARATOR
Intervention: Travel images
Number of subjects: 138
Study 24854041 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump (continuous subcutaneous insulin infusion [CSII])
Number of subjects: 96
Study 24854041 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT)
Number of subjects: 96
Study 24854041 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 96
Study 24854041 — intervention group
Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (SMBG)
Number of subjects: 96
Study 21781200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing exercise (twice daily for 5 minutes over 4 weeks)
Number of subjects: 98
Study 21781200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 98
Study 20643366 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure to six auricular acupoints
Number of subjects: 94
Study 20643366 — intervention group
Group type: COMPARATOR
Intervention: Control group without acupressure
Number of subjects: 94
Study 20643366 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 94
Study 18626263 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of 1% testosterone gel (Testogel)
Number of subjects: 30
Study 18626263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16034518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebeccamycin analogue (RA) 500 mg/m(2) as a 1 hr infusion repeated every 3 weeks (Arm A)
Number of subjects: 42